PedAM
Pediatric Disease Annotations & Medicines
| Disease | dementia |
| Phenotype | C0038868|progressive supranuclear palsy |
| Sentences | 8 |
| PubMedID- 23188965 | Others are multiple system atrophy, dementia with lewy bodies, progressive supranuclear palsy, hemi-parkinsonism-hemiatrophy, juvenile parkinsonism with dystonia and hemiatrophy and primary amyloidosis with parkinsonism. |
| PubMedID- 25853458 | Although the patients described here lacked mnd, close relatives presented a wide range of clinical phenotypes including dementia with parkinsonism, progressive supranuclear palsy and als. |
| PubMedID- 22492994 | In a number of neurodegenerative diseases classified as tauopathies, which include frontotemporal dementia with parkinsonism associated with chromosome 17, progressive supranuclear palsy, corticobasal degeneration, and alzheimer's disease (ad), tau becomes hyperphosphorylated and aggregates into filaments, thus losing the ability to bind and stabilize microtubules (4,5). |
| PubMedID- 24304186 | The study employed a cross-disease, cross-species approach to identify mirna that were either specifically dysregulated in msa or were commonly dysregulated in neurodegenerative conditions such as alzheimer's disease, dementia with lewy bodies, progressive supranuclear palsy and corticobasal degeneration or the tg mouse model equivalents of these disorders. |
| PubMedID- 20798538 | Obsessive-compulsive behavior as a symptom of dementia in progressive supranuclear palsy. |
| PubMedID- 21626553 | During the last decades, atypical parkinsonian disorders such as multiple system atrophy, dementia with lewy bodies, progressive supranuclear palsy, and corticobasal degeneration along with secondary parkinsonian disorders have been increasingly recognized as important causes of parkinsonism. |
| PubMedID- 20129321 | Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. |
| PubMedID- 23962722 | Hyperphosphorylated tau (p-tau) is the primary component of neurofibrillary tangles (nfts), a pathological hallmark of several neurodegenerative diseases including alzheimer's disease (ad), frontotemporal dementia with parkinsonism associated with chromosome 17, progressive supranuclear palsy, corticobasal degeneration and chronic traumatic encephalopathy, which has recently gained significant attention due to sports- and military-related injuries (1–4). |
Page: 1